Insights+ is the GPS that cut through the gridlock of rising costs

Patients can’t coordinate cross benefit therapy. That’s not their job.

October 7, 2020
Insights+ is a web-based platform that helps health plans manage the financial side of improving outcomes. It finds opportunities to reduce the spend of high-cost members, and to optimize outcomes for members with challenging conditions. It does this by providing a simplified view of complex data.

Making smarter business decisions that lead to better outcomes

For many specialty conditions, drug costs comprise the majority of the total cost of care – 70 to 80 percent1 and even more. (Those drug costs may fall under the medical or pharmacy benefit, depending on the condition.)

How patients receive treatment for specialty conditions has evolved. Many specialty drugs used to be given as infusions taken over time, and had to be monitored by a health care professional. More treatments are now available in oral form or as a self injectable that patients can take at home. And many specialty conditions now have several treatment options.


Drug costs as a percentage of total care for some specialty conditions1

A single change can drive millions in savings

The value in findings from Insights+ is only achieved if changes are seen through to implementation. Prime collaborates with health plan clients to design and execute on changes that drive value. A roadmap for changes may include:

  • Verifying contracted rates are billing correctly
  • Comparing site of care use for savings opportunities
  • Identifying high-cost patients with potential overuse opportunities for managed care pharmacy review
  • Controlling for claims outside of network
  • Adhering to negotiated fee schedules
  • Benchmarking provider/physician fees for regional parity

The health plan controls which changes and savings opportunities to pursue. The health plan controls how any interventions are implemented.

Infused savings: Receiving infusions in a hospital outpatient facility can cost two to three times more than alternatives. Lower cost options include: the patient’s home, an independent infusion centers, or at the doctor’s office.

Moving patients from hospital outpatient facilities to their doctors’ offices for infusion services could generate an estimated savings of $1.41 per member per  month. Once changes are implemented, the Insights+ platform can measure the impact. Insights+ provides an automated way to access data that previously had to be looked up manually.

Prime leads the industry in providing health plans the ability to use integrated data to make smarter business decisions. Insights+ has more than one thousand clinical rules to apply to:

  • Finding outliers – claims that aren’t consistent with the product-approved use
  • Seeking out drug duplication and overuse specific to the specialty space
  • Miscoding that might can prevent insurance processing
  • Incorrect billing
  • Dosing inconsistent with drug labeling

Prime knows how to look at total drug spend across medical and pharmacy and understands how drug spend impacts the total cost of care.

Total drug management is the next big opportunity to make a difference in improving health care cost management. And it can be done while improving health outcomes. Prime’s partnership with health plans makes health care work better.

1. Prime and Blue Plan internal sources.

Related news

Perspectives

April 23, 2024

Expert Clinical Network Insights: April 2024

A look at challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance, courtesy of our Expert Clinical Network (ECN) — part of Prime/MRx’s value-based approach to medical and pharmacy benefit management, offering access to more than 175 national and world-renowned key opinion leaders in multiple disease categories

Perspectives

April 23, 2024

April Fraud Focus – How to prioritize drug safety at home  

While ensuring drug safety is often considered the responsibility of pharmaceutical industry players,…

Perspectives

April 19, 2024

AMCP 2024: Behind the Research with Prerak Parikh

Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars